Non-Small Cell Lung CancerEXIMPACTNCT07886359
Effects of Supervised Aerobic Exercise on Biomarkers in Patients With nSCLC Receiving Immunotherapy
A study testing Exercise in people with Non-Small Cell Lung Cancer and Aerobic Exercise, run by Izmir Bakircay University.
Trial summary
Exercise is increasingly recognized as a supportive intervention in oncology and may influence systemic inflammation, immune regulation, physical function, and the tumor microenvironment among patients with non-small cell lung cancer. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Non-Small Cell Lung Cancer, Aerobic Exercise, Immunotherapy
- What is being tested?
- Exercise
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 78 participants
- Where
- No sites listed yet
- Study dates
- 4 Jan 2027to 15 Jun 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Be willing to participate in the study
- Have been diagnosed with nSCLC and be a candidate for immunotherapy
- Having ability to read, write, and communicate in Turkish or English
Who cannot join
- Presence of orthopedic (nerve compression, joint deformity, nerve damage, etc.) and/or neurological (ataxia, history of cerebrovascular events, etc.) deficits or disabilities that would prevent the patient from exercising
- A history of distant metastases diagnosed by a physician and confirmed by imaging studies
- Presence of mental and/or cognitive impairment
- Use of antiepileptic medications
- Pregnancy
- A tendency to bleed (thrombocytopenia)
- Diagnosis of small cell lung cancer
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Investigation of the Effects of Supervised Aerobic Exercise Program on the Immune System and Tumor-Associated Biomarkers in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy: A Single-Blind, Randomized, Controlled Trial
Exercise is increasingly recognized as a supportive intervention in oncology and may influence systemic inflammation, immune regulation, physical function, and the tumor microenvironment among patients with non-small cell lung cancer. The EXIMPACT trial will investigate the effects of a supervised aerobic exercise program on immune system- and tumor microenvironment-related biomarkers in patients with NSCLC receiving active immunotherapy. Although immunotherapy has improved outcomes for patients with NSCLC, factors influencing treatment response and strategies to enhance treatment efficacy remain under investigation.
Read the detailed description
A total of 78 patients with NSCLC receiving active immunotherapy and meeting the predefined eligibility criteria will be enrolled. Participants assigned to the intervention group will perform supervised aerobic exercise on a cycle ergometer twice weekly for 24 weeks. Each session will consist of 5 minutes of warm-up, 30 minutes of aerobic exercise, and 5 minutes of cool-down. Exercise intensity will be prescribed based on estimated maximal oxygen consumption (VO₂max) and progressively increased from 60% during weeks 1-6 to 65% during weeks 7-12, 70% during weeks 13-18, and 75% during weeks 19-24. The exercise program will be implemented in accordance with the American College of Sports Medicine (ACSM) recommendations for exercise oncology. Assessments will be performed at baseline, 12 weeks, and at the end of 24 weeks. The primary outcomes will be immune system- and tumor microenvironment-related biomarkers which will be analyzed via ELISA system (CXCL9, CXCL11, CCL2, CCL5, IFN gamma and IL-10). Immune cells (NK cells, T and B lymphocytes, CD3+, CD4+, CD8+, CD19+, CD16/56+) will also be analyzed via flow-cytometry. Secondary outcomes will include handgrip strength, peripheral muscle strength, quality of life, fatigue, and cardiorespiratory capacity. Progression-free survival will also be evaluated as an exploratory clinical outcome. This study aims to provide prospective evidence regarding the potential immunomodulatory and tumor-related effects of structured aerobic exercise during active immunotherapy and to contribute to the development of individualized supportive exercise strategies for patients with NSCLC.
- Conditions
- Non-Small Cell Lung Cancer, Aerobic Exercise, Immunotherapy, Biomarker, Tumor Microenvironment, Handgrip Strength
- Being tested
- Exercise
- Keywords
- Non-Small cell lung cancer, Exercise, Immunotherapy, Quality of life
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ExerciseOther
Also called Aerobic stationary resistive cycle ergometer
A resistance-based aerobic exercise program using a stationary bike will be implemented twice a week for a total of 24 weeks. Each session will last a total of 40 minutes, consisting of a 5-minute warm-up, a 30-minute exercise period, and a 5-minute cool-down. The moderate-intensity range (60-75% of VO₂max) is defined as the optimal range that is both safe and conducive to physiological adaptation. Exercise intensity will initially be determined based on the estimated VO2max value calculated from each individual's 6-Minute Walk Test result. Based on the clinical value obtained, the initial exercise intensity will be set, and during exercise, heart rate reserve (Karvonen formula) and the Borg Perceived Exertion Scale (target range of 11-14) will be monitored together; if the intensity becomes intolerable, it will be reduced by 5%. If an immune-related adverse event occurs, the exercise will be temporarily suspended.
| Study group | Role | What they receive |
|---|---|---|
| Exercise | Experimental | A resistance-based supervised aerobic exercise program using a stationary cycle ergometer will be conducted twice a week for a total of 24 weeks. Each session will last 40 minutes, consisting of a 5-minute warm-up, a 30-minute workout, and a 5-minute cool-down. Receives: Other: Exercise |
| Control | No intervention | individuals assigned to the control group will receive information on the benefits of physical activity and exercise. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Analysis of Serum Biomarkers (Serum CXCL9,CXCL11,CCL2,CCL5,IFN-γ,IL-10 concentration)
Serum CXCL9,CXCL11,CCL2,CCL5,IFN-γ,IL-10 concentrations will be measured using ELISA. Results will be expressed in pg/mL.
Measured: Before immunotherapy, week 12 and week 24
Assesment of Absolute CD3+ , CD4+ , CD8+ , CD19+ T-lymphocyte counts, CD16/56+ Natural Killer cells
Absolute CD3+ , CD4+ , CD8+ , CD19+ T-lymphocyte counts, CD16/56+ Natural Killer cells will be assessed by flow cytometry using the BD Multitest™ 6-Color TBNK reagent and BD FACSLyric™ flow cytometer. Absolute counts will be calculated using a dual-platform approach incorporating routine complete blood count data. Results will be expressed in cells/µL.
Measured: Before immunotherapy, week 12 and week 24
Analysis of Handgrip Strength
Handgrip strength will be evaluated via hand dynamometer while one is upright seated in an armless chair, elbow flexed 90 degree and forearm positioned at midprone. Three repetitions will be collected, the mean of them will be recorded. Handgrip strength will be recorded as kilogram (kg).
Measured: Before immunotherapy, week 12 and week 24
Peripheral muscle strength
Participants' peripheral muscle strength will be assessed using a digital hand dynamometer (LaFayette Manual Muscle Tester) to measure knee extension of the quadriceps femoris muscle, with three repetitions on each side; measurements will be recorded in Newtons. Peripheral muscle strength will be recorded as Newton (N).
Measured: Before immunotherapy, week 12 and week 24
Cardiorespiratory endurance assessment
Cardiorespiratory endurance will be evaluated via the six minute walk test and total walking distance will be recorded in meters (m).
Measured: Before immunotherapy, week 12 and week 24
Secondary outcomes (7)
Assessment of Quality of Life
Participants' quality of life will be assessed using the European Organization for Research and Treatment of Cancer to assess health-related quality of life in patients with lung cancer questionnaire (EORTC-QLQ-LC29), which was developed specifically for lung cancer patients by the European Organization for Research, Treatment and Cancer and has been proven to be valid and reliable. Higher scores indicate worse quality of life. The minimum and maximum values are ranged between 0 and 100.
Measured: Before immunotherapy, week 12 and week 24
Fatigue Assessment
Fatigue will be assessed using the European Organization for Research and Treatment of Cancer to assess fatigue in patients with cancer (EORTC-QLQ-FA12).Higher scores indicate higher perceived fatigue. The minimum and maximum values are ranged between 0 and 100.
Measured: Before immunotherapy, week 12 and week 24
Body fat percentage
Body fat percentage will be evaluated via Tanita-BC-420 MA. It will be recorded as %(percentage).
Measured: Before immunotherapy, week 12 and week 24
Skeletal Muscle Mass
Skeletal Muscle Mass will be evaluated via Tanita-BC-420 MA. It will be recorded as kilogram (kg).
Measured: Before immunotherapy, week 12 and week 24
Fat free mass
Fat free mass will be evaluated via Tanita-BC-420 MA. It will be recorded as kilogram (kg).
Measured: Before immunotherapy, week 12 and week 24
Mental status assessment
Mental status assessment will be performed via Mini Mental State Examination test. It consists of five domains: orientation (10 points), registration (3 points), attention and calculation (5 points), recall (3 points), and language and visuospatial abilities (9 points). The total score ranges from 0 to 30, with higher scores indicating better cognitive function. Score interpretation is as follows: 24-30 indicates normal cognitive function; 18-23 indicates mild cognitive impairment; 10-17 indicates moderate cognitive impairment; and 0-9 indicates severe cognitive impairment.
Measured: Before immunotherapy, week 12 and week 24
Analysis of Progression-free survival
Progression free survival will be performed during the study's timeframe.
Measured: From enrollment until the end of the 24-month follow-up period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Oct 2026
- Study start4 Jan 2027 (estimated)
- Primary completion15 Mar 2029 (estimated)
- Study completion15 Jun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Non-Small Cell Lung CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A Single-Blind Randomized Controlled Trial
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 78 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Izmir Bakircay University
- Sponsor type
- University, hospital or other
- Collaborators
- The Scientific and Technological Research Council of Turkey
- Responsible party
- Principal investigator, Alper Tuğral, Izmir Bakircay University
- Investigators
- Alper Tuğral, Assoc.Prof, Principal investigator, Izmir Bakircay UniversityGözde Kaya Uçar, Assist.Prof, Study chair, Izmir Bakircay UniversityMurat Akyol, MD, Prof., Study chair, Izmir Bakircay UniversityMelih Zeren, Assoc.Prof, Study chair, Izmir Bakircay UniversityFatma D Arslan, MD, Prof., Study chair, Izmir Bakircay UniversityMutlu O Güçsav, MD, Study chair, Izmir Bakircay UniversityRasime D Kılıçoğlu, MD, Study chair, Izmir City HospitalEzgisu Türker, PT, Study chair, Izmir Bakircay University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07886359
- Sponsor's protocol ID
- BakircayU-nSCLC
- Other IDs
- 226S466
- Acronym
- EXIMPACT
- Status last verified
- Oct 2026
- First submitted
- 8 Oct 2026
- Last updated
- 21 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared publicly or with other researchers due to participant privacy and confidentiality considerations.
Publications
Gouez M, Perol O, Pialoux V, Avrillon V, Boussageon M, Decroisette C, Delrieu L, El Hajj H, Fournier B, Gille R, His M, Mastroianni B, Swalduz A, Perol M, Fervers B. Feasibility and Preliminary Efficacy of Aerobic Acute Exercise Prior to Immunotherapy and Chemotherapy Infusion in Patients with Metastatic Non-Small Cell Lung Cancer: A Randomized Controlled Trial. J Clin Med. 2026 Jan 1;15(1):334. doi: 10.3390/jcm15010334.
PubMed 41517582Yan H, Jiang A, Huang Y, Zhang J, Yang W, Zhang W, Liu T. Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma. Front Immunol. 2023 Oct 9;14:1265914. doi: 10.3389/fimmu.2023.1265914. eCollection 2023.
PubMed 37876940Ramachandran S, Verma AK, Dev K, Goyal Y, Bhatt D, Alsahli MA, Rahmani AH, Almatroudi A, Almatroodi SA, Alrumaihi F, Khan NA. Role of Cytokines and Chemokines in NSCLC Immune Navigation and Proliferation. Oxid Med Cell Longev. 2021 Jul 16;2021:5563746. doi: 10.1155/2021/5563746. eCollection 2021.
PubMed 34336101Quist M, Adamsen L, Rorth M, Laursen JH, Christensen KB, Langer SW. The Impact of a Multidimensional Exercise Intervention on Physical and Functional Capacity, Anxiety, and Depression in Patients With Advanced-Stage Lung Cancer Undergoing Chemotherapy. Integr Cancer Ther. 2015 Jul;14(4):341-9. doi: 10.1177/1534735415572887. Epub 2015 Mar 22.
PubMed 25800229Miao SN, Chai MQ, Liu XY, Wei CY, Zhang CC, Sun NN, Fei QZ, Peng LL, Qiu H. Exercise accelerates recruitment of CD8+ T cell to promotes anti-tumor immunity in lung cancer via epinephrine. BMC Cancer. 2024 Apr 15;24(1):474. doi: 10.1186/s12885-024-12224-7.
PubMed 38622609Martin-Ruiz A, Fiuza-Luces C, Rincon-Castanedo C, Fernandez-Moreno D, Galvez BG, Martinez-Martinez E, Martin-Acosta P, Coronado MJ, Franco-Luzon L, Gonzalez-Murillo A, Ramirez M, Provencio M, Lucia A. Benefits of exercise and immunotherapy in a murine model of human non-small-cell lung carcinoma. Exerc Immunol Rev. 2020;26:100-115.
PubMed 32139351Liu J, Liu W, Wan Y, Mao W. Crosstalk between Exercise and Immunotherapy: Current Understanding and Future Directions. Research (Wash D C). 2024 Apr 25;7:0360. doi: 10.34133/research.0360. eCollection 2024.
PubMed 38665847
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of the Effects of Supervised Aerobic Exercise Program on the Immune System and Tumor-Associated Biomarkers in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy: A Single-Blind, Randomized, Controlled Trial
- ClinicalTrials.gov ID
- NCT07886359
- Acronym / sponsor ID
- EXIMPACT / BakircayU-nSCLC
- Conditions
- Non-Small Cell Lung Cancer, Aerobic Exercise, Immunotherapy, Biomarker, Tumor Microenvironment, Handgrip Strength
- Keywords
- Non-Small cell lung cancer, Exercise, Immunotherapy, Quality of life
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 78 participants (estimated)
- Lead sponsor
- Izmir Bakircay UniversityUniversity, hospital or other
- Collaborators
- The Scientific and Technological Research Council of Turkey
- Study start
- 4 Jan 2027 (estimated)
- Primary completion
- 15 Mar 2029 (estimated)
- Study completion
- 15 Jun 2029 (estimated)
- First posted
- 21 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Exercise is increasingly recognized as a supportive intervention in oncology and may influence systemic inflammation, immune regulation, physical function, and the tumor microenvironment among patients with non-small cell lung cancer. The EXIMPACT trial will investigate the effects of a supervised aerobic exercise program on immune system- and tumor microenvironment-related biomarkers in patients with NSCLC receiving active immunotherapy. Although immunotherapy has improved outcomes for patients with NSCLC, factors influencing treatment response and strategies to enhance treatment efficacy remain under investigation.
Detailed description
A total of 78 patients with NSCLC receiving active immunotherapy and meeting the predefined eligibility criteria will be enrolled. Participants assigned to the intervention group will perform supervised aerobic exercise on a cycle ergometer twice weekly for 24 weeks. Each session will consist of 5 minutes of warm-up, 30 minutes of aerobic exercise, and 5 minutes of cool-down. Exercise intensity will be prescribed based on estimated maximal oxygen consumption (VO₂max) and progressively increased from 60% during weeks 1-6 to 65% during weeks 7-12, 70% during weeks 13-18, and 75% during weeks 19-24. The exercise program will be implemented in accordance with the American College of Sports Medicine (ACSM) recommendations for exercise oncology. Assessments will be performed at baseline, 12 weeks, and at the end of 24 weeks. The primary outcomes will be immune system- and tumor microenvironment-related biomarkers which will be analyzed via ELISA system (CXCL9, CXCL11, CCL2, CCL5, IFN gamma and IL-10). Immune cells (NK cells, T and B lymphocytes, CD3+, CD4+, CD8+, CD19+, CD16/56+) will also be analyzed via flow-cytometry. Secondary outcomes will include handgrip strength, peripheral muscle strength, quality of life, fatigue, and cardiorespiratory capacity. Progression-free survival will also be evaluated as an exploratory clinical outcome. This study aims to provide prospective evidence regarding the potential immunomodulatory and tumor-related effects of structured aerobic exercise during active immunotherapy and to contribute to the development of individualized supportive exercise strategies for patients with NSCLC.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
- Model description
- A Single-Blind Randomized Controlled Trial
| Arm | Type | Receives |
|---|---|---|
| Exercise | Experimental | Other: ExerciseA resistance-based supervised aerobic exercise program using a stationary cycle ergometer will be conducted twice a week for a total of 24 weeks. Each session will last 40 minutes, consisting of a 5-minute warm-up, a 30-minute workout, and a 5-minute cool-down. |
| Control | No intervention | –individuals assigned to the control group will receive information on the benefits of physical activity and exercise. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Be willing to participate in the study
- Have been diagnosed with nSCLC and be a candidate for immunotherapy
- Having ability to read, write, and communicate in Turkish or English
Key exclusion criteria (7 listed)
- Presence of orthopedic (nerve compression, joint deformity, nerve damage, etc.) and/or neurological (ataxia, history of cerebrovascular events, etc.) deficits or disabilities that would prevent the patient from exercising
- A history of distant metastases diagnosed by a physician and confirmed by imaging studies
- Presence of mental and/or cognitive impairment
- Use of antiepileptic medications
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ExerciseAlso: Aerobic stationary resistive cycle ergometerA resistance-based aerobic exercise program using a stationary bike will be implemented twice a week for a total of 24 weeks. Each session will last a total of 40 minutes, consisting of a 5-minute warm-up, a 30-minute exercise period, and a 5-minute cool-down. The moderate-intensity range (60-75% of VO₂max) is defined as the optimal range that is both safe and conducive to physiological adaptation. Exercise intensity will initially be determined based on the estimated VO2max value calculated from each individual's 6-Minute Walk Test result. Based on the clinical value obtained, the initial exercise intensity will be set, and during exercise, heart rate reserve (Karvonen formula) and the Borg Perceived Exertion Scale (target range of 11-14) will be monitored together; if the intensity becomes intolerable, it will be reduced by 5%. If an immune-related adverse event occurs, the exercise will be temporarily suspended. | Other | Exercise |
Primary outcome
Analysis of Serum Biomarkers (Serum CXCL9,CXCL11,CCL2,CCL5,IFN-γ,IL-10 concentration)
Time frame: Before immunotherapy, week 12 and week 24
Serum CXCL9,CXCL11,CCL2,CCL5,IFN-γ,IL-10 concentrations will be measured using ELISA. Results will be expressed in pg/mL.
Assesment of Absolute CD3+ , CD4+ , CD8+ , CD19+ T-lymphocyte counts, CD16/56+ Natural Killer cells
Time frame: Before immunotherapy, week 12 and week 24
Absolute CD3+ , CD4+ , CD8+ , CD19+ T-lymphocyte counts, CD16/56+ Natural Killer cells will be assessed by flow cytometry using the BD Multitest™ 6-Color TBNK reagent and BD FACSLyric™ flow cytometer. Absolute counts will be calculated using a dual-platform approach incorporating routine complete blood count data. Results will be expressed in cells/µL.
Analysis of Handgrip Strength
Time frame: Before immunotherapy, week 12 and week 24
Handgrip strength will be evaluated via hand dynamometer while one is upright seated in an armless chair, elbow flexed 90 degree and forearm positioned at midprone. Three repetitions will be collected, the mean of them will be recorded. Handgrip strength will be recorded as kilogram (kg).
Peripheral muscle strength
Time frame: Before immunotherapy, week 12 and week 24
Participants' peripheral muscle strength will be assessed using a digital hand dynamometer (LaFayette Manual Muscle Tester) to measure knee extension of the quadriceps femoris muscle, with three repetitions on each side; measurements will be recorded in Newtons. Peripheral muscle strength will be recorded as Newton (N).
Cardiorespiratory endurance assessment
Time frame: Before immunotherapy, week 12 and week 24
Cardiorespiratory endurance will be evaluated via the six minute walk test and total walking distance will be recorded in meters (m).
7 secondary outcomes
Assessment of Quality of Life
Time frame: Before immunotherapy, week 12 and week 24
Fatigue Assessment
Time frame: Before immunotherapy, week 12 and week 24
Body fat percentage
Time frame: Before immunotherapy, week 12 and week 24
Skeletal Muscle Mass
Time frame: Before immunotherapy, week 12 and week 24
Fat free mass
Time frame: Before immunotherapy, week 12 and week 24
Mental status assessment
Time frame: Before immunotherapy, week 12 and week 24
Analysis of Progression-free survival
Time frame: From enrollment until the end of the 24-month follow-up period
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2026.
- Background: PubMed 41517582Gouez M, Perol O, Pialoux V, Avrillon V, Boussageon M, Decroisette C, Delrieu L, El Hajj H, Fournier B, Gille R, His M, Mastroianni B, Swalduz A, Perol M, Fervers B. Feasibility and Preliminary Efficacy of Aerobic Acute Exercise Prior to Immunotherapy and Chemotherapy Infusion in Patients with Metastatic Non-Small Cell Lung Cancer: A Randomized Controlled Trial. J Clin Med. 2026 Jan 1;15(1):334. doi: 10.3390/jcm15010334.
- Background: PubMed 37876940Yan H, Jiang A, Huang Y, Zhang J, Yang W, Zhang W, Liu T. Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma. Front Immunol. 2023 Oct 9;14:1265914. doi: 10.3389/fimmu.2023.1265914. eCollection 2023.
- Background: PubMed 34336101Ramachandran S, Verma AK, Dev K, Goyal Y, Bhatt D, Alsahli MA, Rahmani AH, Almatroudi A, Almatroodi SA, Alrumaihi F, Khan NA. Role of Cytokines and Chemokines in NSCLC Immune Navigation and Proliferation. Oxid Med Cell Longev. 2021 Jul 16;2021:5563746. doi: 10.1155/2021/5563746. eCollection 2021.
- Background: PubMed 25800229Quist M, Adamsen L, Rorth M, Laursen JH, Christensen KB, Langer SW. The Impact of a Multidimensional Exercise Intervention on Physical and Functional Capacity, Anxiety, and Depression in Patients With Advanced-Stage Lung Cancer Undergoing Chemotherapy. Integr Cancer Ther. 2015 Jul;14(4):341-9. doi: 10.1177/1534735415572887. Epub 2015 Mar 22.
- Background: PubMed 38622609Miao SN, Chai MQ, Liu XY, Wei CY, Zhang CC, Sun NN, Fei QZ, Peng LL, Qiu H. Exercise accelerates recruitment of CD8+ T cell to promotes anti-tumor immunity in lung cancer via epinephrine. BMC Cancer. 2024 Apr 15;24(1):474. doi: 10.1186/s12885-024-12224-7.
- Background: PubMed 32139351Martin-Ruiz A, Fiuza-Luces C, Rincon-Castanedo C, Fernandez-Moreno D, Galvez BG, Martinez-Martinez E, Martin-Acosta P, Coronado MJ, Franco-Luzon L, Gonzalez-Murillo A, Ramirez M, Provencio M, Lucia A. Benefits of exercise and immunotherapy in a murine model of human non-small-cell lung carcinoma. Exerc Immunol Rev. 2020;26:100-115.
- Background: PubMed 38665847Liu J, Liu W, Wan Y, Mao W. Crosstalk between Exercise and Immunotherapy: Current Understanding and Future Directions. Research (Wash D C). 2024 Apr 25;7:0360. doi: 10.34133/research.0360. eCollection 2024.
- Individual participant dataSharing planned: No. Individual participant data will not be shared publicly or with other researchers due to participant privacy and confidentiality considerations.
Related trials for Non-Small Cell Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Alper Tuğral, Assoc.Prof principal investigator
Izmir Bakircay University
Gözde Kaya Uçar, Assist.Prof study chair
Izmir Bakircay University
Murat Akyol, MD, Prof. study chair
Izmir Bakircay University
Questions about this trial
What is this clinical trial studying?
A study testing Exercise in people with Non-Small Cell Lung Cancer and Aerobic Exercise, run by Izmir Bakircay University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Alper Tuğral, Assoc.Prof (+902324930000 ext. 11259, alper.tugral@bakircay.edu.tr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Analysis of Serum Biomarkers (Serum CXCL9,CXCL11,CCL2,CCL5,IFN-γ,IL-10 concentration) (time frame: Before immunotherapy, week 12 and week 24). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07886359, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.